Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

CFDA grants approval for clinical trials of fadanafil

Dec. 16, 2016

Third Rock Ventures launches Goldfinch Bio with a focus on therapies for kidney disease

Dec. 15, 2016

Topline data from phase III PATENCY-1 study of investigational vonapanitase in patients with CKD

Dec. 14, 2016

Blisibimod BRIGHT-SC study demonstrates positive trends in the week 48 analysis

Dec. 9, 2016

Regulus unveils new drug development candidates

Dec. 9, 2016

Anti-APRIL monoclonal antibody developed at Visterra for IgA nephropathy

Dec. 7, 2016

Pharmalink's Nefecon earns orphan drug designation in E.U. for IgAN

Nov. 30, 2016

MonoSol files NDA with FDA for Tadalafil PharmFilm in the treatment of erectile dysfunction

Nov. 29, 2016

Enrollment completed in phase IIa study of Serodus' SER-150

Nov. 28, 2016

RGC upregulation may have a pathogenic role in lupus nephritis

Nov. 24, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...